CL2021000678A1 - Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2) - Google Patents

Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2)

Info

Publication number
CL2021000678A1
CL2021000678A1 CL2021000678A CL2021000678A CL2021000678A1 CL 2021000678 A1 CL2021000678 A1 CL 2021000678A1 CL 2021000678 A CL2021000678 A CL 2021000678A CL 2021000678 A CL2021000678 A CL 2021000678A CL 2021000678 A1 CL2021000678 A1 CL 2021000678A1
Authority
CL
Chile
Prior art keywords
glp
analogs
glucagon
peptide
formulations
Prior art date
Application number
CL2021000678A
Other languages
English (en)
Inventor
Lise Giehm
Claes Melander
Eva Horn Møller
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2021000678A1 publication Critical patent/CL2021000678A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

Se describen formulaciones líquidas de análogos del GLP-2 que las hacen adecuadas para un almacenamiento a largo plazo como líquidos y/o que las hacen especialmente adecuadas para su administración mediante un dispositivo de administración de fármacos. También se describen composiciones sólidas que comprenden sales de acetato de análogos del péptido similar a glucagón tipo 2 (GLP-2) útiles para preparar las formulaciones líquidas.
CL2021000678A 2018-09-28 2021-03-19 Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2) CL2021000678A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18197755.4A EP3628683A1 (en) 2018-09-28 2018-09-28 Formulations of glucagon-like-peptide-2 (glp-2) analogues

Publications (1)

Publication Number Publication Date
CL2021000678A1 true CL2021000678A1 (es) 2021-08-06

Family

ID=63794308

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000678A CL2021000678A1 (es) 2018-09-28 2021-03-19 Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2)

Country Status (13)

Country Link
US (2) US20220265551A1 (es)
EP (2) EP3628683A1 (es)
JP (1) JP2022502432A (es)
KR (1) KR20210069056A (es)
CN (1) CN112771073A (es)
AU (1) AU2019348538A1 (es)
BR (1) BR112021005858A2 (es)
CA (1) CA3114330A1 (es)
CL (1) CL2021000678A1 (es)
IL (1) IL281362A (es)
MX (1) MX2021003271A (es)
SG (1) SG11202102383VA (es)
WO (1) WO2020065064A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154869A1 (en) * 2020-05-22 2023-03-29 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2
US20240091317A1 (en) * 2020-12-16 2024-03-21 Zealand Pharma A/S Use of glp-2 analogues in patients with renal insufficiency
AU2022341538A1 (en) * 2021-09-10 2024-04-11 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
WO2023118416A1 (en) 2021-12-23 2023-06-29 Zealand Pharma A/S Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
WO2024068933A1 (en) 2022-09-30 2024-04-04 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
WO2024075135A1 (en) * 2022-10-03 2024-04-11 Orbicular Pharmaceutical Technologies Private Limited "stable injectable compositions of glp-2 peptide"

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
EP1231219B1 (en) 1996-04-12 2010-08-25 1149336 Ontario Inc. GLucagon-like peptide-2 analogs
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EA006160B1 (ru) 2001-02-16 2005-10-27 Конджачем, Инк. Долгоживущий глюкагоноподобный пептид 2(glp-2, гпп-2) для лечения желудочно-кишечных заболеваний и расстройств
KR101242795B1 (ko) 2005-05-04 2013-03-12 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
WO2007074010A1 (en) * 2005-12-24 2007-07-05 Teagasc Dairy Products Research Centre Process for the production of trans-10, cis 12 octadecadienoic acid
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
EP2051995B1 (en) * 2006-11-08 2017-02-08 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
KR20130115086A (ko) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
FR2994390B1 (fr) * 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
EA202191513A1 (ru) * 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
BR112019010236A2 (pt) * 2016-11-21 2019-08-20 Eiger Biopharmaceuticals Inc formulações tamponadas de exendina (9-39)

Also Published As

Publication number Publication date
SG11202102383VA (en) 2021-04-29
CA3114330A1 (en) 2020-04-02
WO2020065064A1 (en) 2020-04-02
US20240065978A1 (en) 2024-02-29
JP2022502432A (ja) 2022-01-11
BR112021005858A2 (pt) 2021-07-27
MX2021003271A (es) 2021-05-12
US20220265551A1 (en) 2022-08-25
EP3628683A1 (en) 2020-04-01
AU2019348538A1 (en) 2021-05-20
KR20210069056A (ko) 2021-06-10
EP3856766A1 (en) 2021-08-04
CN112771073A (zh) 2021-05-07
IL281362A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2021000678A1 (es) Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2)
NI201700063A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
UY37686A (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CO2018002026A2 (es) Composiciones de insulina de rápida acción
AR110299A1 (es) Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
CL2019001541A1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros (divisional solicitud 201700896)
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
PE20200746A1 (es) AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
CL2016001472A1 (es) Nuevo compuesto análogo del glucagón constituido por una secuencia aminoacídica asociada con un ácido alfa aminobutírico, formulación farmacéutica que la comprende y su uso para el tratamiento de hipoglicemia severa.
ECSP21079422A (es) Método para preparar formulaciones de péptidos estables
CL2019002899A1 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4.
EA201991594A1 (ru) Депо-препарат